Mieko Ogino1, Aki Shiozawa2, Hiroyuki Ota3, Shuichi Okamoto3, Shinzo Hiroi3, Izumi Kawachi4. 1. International University of Health & Welfare, School of Medicine, Center for Medical Education, 4-2 Kozunomori, Narita, Chiba, 286-8686, Japan. 2. Takeda Pharmaceuticals International Inc., 1 Takeda Parkway, Deerfield, IL 60015, USA. 3. Japan Medical Affairs - Japan, Takeda Pharmaceutical Company Ltd, 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo, Japan. 4. Department of Neurology, Brain Research Institute, Niigata University, 1-757 Asahimachidori, Chuo-ku, Niigata 951-8585, Japan.
Abstract
AIM: Use real-world data to investigate the treatment, comorbidities and prevalence of multiple sclerosis (MS) in an employed Japanese population. METHODS: Data from the Japanese Medical Data Center health insurance claims database were analyzed (January 2005-November 2014). Patients with claims associated with an MS diagnosis were identified (n = 494) and comorbidities and prescribed treatments were investigated. MS prevalence within the database was calculated for each calendar year (2011-2013) Results: IFN-β and prednisolone were the most commonly prescribed treatments. Common comorbidities included astigmatism and gastric ulcer. Within the database, MS prevalence increased from 0.015 to 0.016%. CONCLUSION: MS prevalence increased from 2011 to 2013. Some comorbidities were considered unrelated to MS owing to how physicians use disease codes for reimbursement.
AIM: Use real-world data to investigate the treatment, comorbidities and prevalence of multiple sclerosis (MS) in an employed Japanese population. METHODS: Data from the Japanese Medical Data Center health insurance claims database were analyzed (January 2005-November 2014). Patients with claims associated with an MS diagnosis were identified (n = 494) and comorbidities and prescribed treatments were investigated. MS prevalence within the database was calculated for each calendar year (2011-2013) Results: IFN-β and prednisolone were the most commonly prescribed treatments. Common comorbidities included astigmatism and gastric ulcer. Within the database, MS prevalence increased from 0.015 to 0.016%. CONCLUSION: MS prevalence increased from 2011 to 2013. Some comorbidities were considered unrelated to MS owing to how physicians use disease codes for reimbursement.